Chang Shiou-Chi, Seneviratne Uthpala I, Wu Jie, Tretyakova Natalia, Essigmann John M
Department of Medicinal Chemistry and the Masonic Cancer Center, University of Minnesota , Minneapolis, Minnesota 55455, United States.
Chem Res Toxicol. 2017 May 15;30(5):1230-1239. doi: 10.1021/acs.chemrestox.7b00064. Epub 2017 Apr 17.
The adverse effects of the human carcinogen 1,3-butadiene (BD) are believed to be mediated by its DNA-reactive metabolites such as 3,4-epoxybut-1-ene (EB) and 1,2,3,4-diepoxybutane (DEB). The specific DNA adducts responsible for toxic and mutagenic effects of BD, however, have yet to be identified. Recent in vitro polymerase bypass studies of BD-induced adenine (BD-dA) adducts show that DEB-induced N,N-DHB-dA (DHB = 2,3-dihydroxybutan-1,4-diyl) and 1,N-γ-HMHP-dA (HMHP = 2-hydroxy-3-hydroxymethylpropan-1,3-diyl) adducts block replicative DNA polymerases but are bypassed by human polymerases η and κ, leading to point mutations and deletions. In contrast, EB-induced N-HB-dA (HB = 2-hydroxy-3-buten-1-yl) does not block DNA synthesis and is nonmutagenic. In the present study, we employed a newly established in vivo lesion-induced mutagenesis/genotoxicity assay via next-generation sequencing to evaluate the in vivo biological consequences of S-N-HB-dA, R,R-N,N-DHB-dA, S,S-N,N-DHB-dA, and R,S-1,N-γ-HMHP-dA. In addition, the effects of AlkB-mediated direct reversal repair, MutM and MutY catalyzed base excision repair, and DinB translesion synthesis on the BD-dA adducts in bacterial cells were investigated. BD-dA adducts showed the expected inhibition of DNA replication in vivo but were not substantively mutagenic in any of the genetic environments investigated. This result is in contrast with previous in vitro observations and opens the possibility that E. coli repair and bypass systems other than the ones studied here are able to minimize the mutagenic properties of BD-dA adducts.
人类致癌物1,3 - 丁二烯(BD)的不良反应被认为是由其具有DNA反应活性的代谢产物介导的,如3,4 - 环氧丁 - 1 - 烯(EB)和1,2,3,4 - 二环氧丁烷(DEB)。然而,导致BD产生毒性和致突变作用的特定DNA加合物尚未被鉴定出来。最近关于BD诱导的腺嘌呤(BD - dA)加合物的体外聚合酶绕过研究表明,DEB诱导的N,N - DHB - dA(DHB = 2,3 - 二羟基丁 - 1,4 - 二基)和1,N - γ - HMHP - dA(HMHP = 2 - 羟基 - 3 - 羟甲基丙 - 1,3 - 二基)加合物会阻断复制性DNA聚合酶,但人类聚合酶η和κ能绕过它们,导致点突变和缺失。相比之下,EB诱导的N - HB - dA(HB = 2 - 羟基 - 3 - 丁烯 - 1 - 基)不会阻断DNA合成,且无致突变性。在本研究中,我们采用了一种新建立的通过下一代测序进行体内损伤诱导的诱变/遗传毒性测定方法,以评估S - N - HB - dA、R,R - N,N - DHB - dA、S,S - N,N - DHB - dA和R,S - 1,N - γ - HMHP - dA的体内生物学后果。此外,还研究了AlkB介导的直接逆转修复、MutM和MutY催化的碱基切除修复以及DinB跨损伤合成对细菌细胞中BD - dA加合物的影响。BD - dA加合物在体内显示出预期的DNA复制抑制作用,但在所研究的任何遗传环境中都没有实质性的致突变性。这一结果与之前的体外观察结果相反,并表明除了本文研究的系统外,大肠杆菌的其他修复和绕过系统可能能够将BD - dA加合物的致突变特性降至最低。